Want to see AU:CMB full AI Analyst Report?
CMB Stock Chart & Stats
AU$0.47
-AU$0.02(-4.44%)
At close: 4:00 PM EST
AU$0.47
-AU$0.02(-4.44%)
Day’s Range― - ―
52-Week RangeAU$0.34 - AU$0.60
Previous CloseN/A
Volume21.69K
Average Volume (3M)5.82K
Market Cap
AU$14.72M
Enterprise ValueAU$9.96
Total Cash (Recent Filing)AU$1.12M
Total Debt (Recent Filing)AU$149.80K
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding29,431,917
10 Day Avg. Volume1,882
30 Day Avg. Volume5,817
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.31
Price to Sales (P/S)15.99
P/FCF Ratio-3.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive EquityThe shift from negative to positive shareholders’ equity indicates a materially stronger capital position than in 2023. Maintaining positive equity provides a more stable base for continued development and reduces the immediate balance-sheet strain associated with accumulated deficits.
Lower DebtDebt reduction improves financial flexibility and lowers the burden of fixed obligations while the company remains loss-making. Moderate leverage gives management more capacity to allocate resources toward development and commercialization rather than servicing a large debt load.
Revenue RecoveryThe return to measurable revenue after near-zero sales in 2022–2023 shows that commercial activity has not disappeared and that products or related channels are generating some receipts. This provides a foundation for future growth if commercialization efforts scale.
Bears Say
Persistent LossesSeveral consecutive years of operating losses show that the business has not yet established sustainable profitability. Continued losses can consume capital, constrain reinvestment, and increase reliance on external funding while products and therapies remain in development.
Negative Cash FlowPersistent negative operating and free cash flow means the company is not currently funding its activities from internally generated cash. Sustained burn increases funding and potential dilution risk, particularly if commercialization does not improve cash generation.
Small, Volatile RevenueRevenue remains small relative to the company’s operating losses and has been highly volatile across reporting years. The decline in 2026 after the recent rebound highlights limited commercial consistency, making it harder to absorb fixed costs or reach profitability.
Regeneus Ltd. News
CMB FAQ
What was Regeneus Ltd.’s price range in the past 12 months?
Regeneus Ltd. lowest share price was AU$0.34 and its highest was AU$0.60 in the past 12 months.
What is Regeneus Ltd.’s market cap?
Regeneus Ltd.’s market cap is AU$14.72M.
When is Regeneus Ltd.’s upcoming earnings report date?
Regeneus Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 165 days.
How were Regeneus Ltd.’s earnings last quarter?
Regeneus Ltd. released its earnings results on Aug 28, 2026. The company reported -AU$0.104 earnings per share for the quarter.
Is Regeneus Ltd. overvalued?
According to Wall Street analysts Regeneus Ltd.’s price is currently Overvalued.
Does Regeneus Ltd. pay dividends?
Regeneus Ltd. does not currently pay dividends.
What is Regeneus Ltd.’s EPS estimate?
Regeneus Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regeneus Ltd. have?
Regeneus Ltd. has 29,431,917 shares outstanding.
What happened to Regeneus Ltd.’s price movement after its last earnings report?
Regeneus Ltd. reported an EPS of -AU$0.104 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Regeneus Ltd.?
Currently, no hedge funds are holding shares in AU:CMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneus Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Regeneus Ltd.
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―